Nuria Gonzalez-Sala

Girona, CT 17007, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.

Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.

Journal: Cancers

Published: May 22, 2026

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Journal: International journal of molecular sciences

Published: May 30, 2025

Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964].

Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964].

Journal: European urology oncology

Published: May 27, 2025

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

Journal: Oncology reviews

Published: March 24, 2025

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.

Journal: European urology oncology

Published: January 13, 2025

Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.

Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.

Journal: Actas urologicas espanolas

Published: March 05, 2024

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma.

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma.

Journal: Frontiers in oncology

Published: December 11, 2023

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.

Journal: European urology oncology

Published: October 31, 2023

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: July 25, 2023

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2023

Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature.

Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature.

Journal: Frontiers in oncology

Published: May 23, 2023

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer.

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer.

Journal: Frontiers in oncology

Published: August 12, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026